Losartan Potassium
Product Images NDC 53002-2638

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-2638). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530022638)

Losartan Potassium 100mg tablets carton label from RPK Pharmaceuticals, Inc. The package contains 30 tablets with instructions to take one tablet daily or as directed. The label includes prescription information, barcodes, NDC number 53002-2638-30, lot number, expiration date, and storage instructions. A placeholder for clinic name and patient name is also present.*

FDA Label Image

Losartan Fig1

A line graph comparing the percentage of patients with a primary endpoint over time (up to 66 months) between Losartan Potassium and Atenolol. The x-axis represents the study months, and the y-axis shows the percentage of patients. The graph shows adjusted risk reduction for Losartan Potassium at 13% with a p-value of 0.021.*

FDA Label Image

Losartan Fig2

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months between Atenolol and Losartan Potassium. The graph shows adjusted risk reduction of 25% with a p-value of 0.001. The x-axis represents study months, and the y-axis represents the percentage of patients with stroke.*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol. It includes hazard ratios with 95% confidence intervals for overall results, age groups, gender, race, ischemic heart disease status, diabetes status, and history of cardiovascular disease. Two charts compare primary composite events and stroke (fatal/non-fatal) event rates.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with events over time (in months) between Losartan Potassium and placebo groups. The solid line represents Losartan Potassium, and the dashed line represents placebo. The graph includes a noted risk reduction of 16.1% with a p-value of 0.022, indicating statistical significance.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of losartan potassium, showing its molecular components and arrangement including the distinctive biphenyl and tetrazole groups with potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.